Peptides for Body Recomposition Research 2026 — Fat Loss and Muscle Preservation Mechanisms

Body recomposition research is inherently multi-mechanism: fat mass reduction and lean mass preservation or gain involve different biological pathways, and no single compound addresses both optimally. This is what drives the research interest in combining compounds across the GLP, GH-axis, and IGF-1 categories.

GLP-Class Compounds for Fat Mass Research

Retatrutide, Tirzepatide, and Semaglutide address the fat loss side of recomposition through appetite suppression and metabolic mechanisms documented in weight loss research. However, a consistent finding in GLP-class weight loss trials is that a portion of weight lost comes from lean mass alongside fat mass — a finding that has driven research interest in combining GLP-class compounds with lean-mass-preserving agents.

GH-Axis Compounds for Lean Mass Preservation

Growth hormone and GH secretagogue research addresses the lean mass side: GH-axis stimulation promotes protein synthesis, lipolysis, and IGF-1-mediated anabolic signaling that preferentially preserves or builds muscle tissue even in a caloric deficit. CJC-1295, Ipamorelin, and Tesamorelin are studied specifically for GH-mediated body composition effects including visceral fat reduction and lean mass support.

IGF-1 Research in Recomposition Contexts

IGF-1 LR3 addresses muscle tissue specifically through direct IGF-1 receptor activation, stimulating satellite cell proliferation and protein synthesis independently of the GH-pituitary axis. In recomposition research designs, IGF-1 analogs allow researchers to study anabolic receptor stimulation at the muscle tissue level while GLP-class compounds manage the fat mass and appetite variables separately.

Research Use Only. DisclaimerFor laboratory and research use only. Not for human consumption. This content is educational and does not constitute medical advice.